Document is current
Any future updates will be listed below
-
Authors
Shi, Yuankai http://orcid.org/0000-0002-8685-6744
Zhou, Jianying
Zhao, Yanqiu
Zhu, Bo
Zhang, Liangming
Li, Xingya
Fang, Jian
Shi, Jianhua
Zhuang, Zhixiang
Yang, Sheng
Wang, Donglin
Yu, Huiqing
Zhang, Longzhen
Zheng, Rongsheng
Greco, Michael
Wang, Tingting
-
Funding
Funding for this research was provided by:
China National Major Project for New Drug Innovation (2017ZX09304015)
New National Natural Science Foundation of China (82172856, 81972805)
- License Information
-
More Information
Article History
Received: 24 May 2022
Accepted: 1 December 2022
First Online: 8 January 2023
Declarations
:
: This study was first approved by the Ethics Committee of the National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, and the approval number was 17–056/1311. This study was carried out in accordance with the protocol and complied with ICH-GCP and GCP (the People’s Republic of China), the Declaration of Helsinki, and other relevant laws and regulations. Written informed consent signed and dated by the patients has been obtained.
: Not applicable.
: MG and TTW are employees of Beta Pharma, and all other authors declare no competing interests.
